Latest From Adimab LLC
Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.
California-based Tizona has begun 2019 by installing a new CEO and winning a lucrative early-stage R&D pact with AbbVie aimed at commercializing cancer therapies targeting the immune system-suppressing enzyme CD39.
Medicines regulators have cleared Innovent Biologics's anti-PD-1 therapy, sintilimab, for classical Hodgkin's lymphoma in China, where late-stage studies as a first-line therapy for advanced esopheageal cancer have also just started.
Scrip spoke with Managing Director Julie Sunderland about Biomatics' new $300m fund. Also, Silicon Valley Bank reveals its surprising Leerink buy, Perceptive Advisors raises $675m, Roivant brings in another $200m, and cell and gene therapy financings surge in the third quarter.
- Drug Discovery Tools
- Therapeutic Areas
- Adimab Inc.
- North America
- Parent & Subsidiaries
- Adimab LLC
- Senior Management
Tillman Gerngross, PhD, CEO & Co-Founder
Guy Van Meter, SVP, Head of Bus. Dev.
K. Dane Wittrup, PhD, Co-Founder & Chairman of the SAB
Eric Krauland, PhD, CSO
Ryan McGovern, SVP, Finance & Ops
Max Vasquez, SIte Head & SVP Computational Biology
- Contact Info
Phone: (603) 643-7110
7 Lucent Dr.
Lebanon, NH 03766
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.